Format

Send to

Choose Destination
Oncotarget. 2015 Oct 20;6(32):33982-92. doi: 10.18632/oncotarget.5053.

Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: implications for clinical management.

Author information

1
Medical Oncology, AO Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy.
2
Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
3
Medical Oncology, Fondazione Poliambulanza, Brescia, Italy.
4
Medical Oncology, Azienda Ospedaliero-Universitaria "S. Maria della Misericordia", Udine, Italy.
5
Medical Oncology, Azienda Ospedaliero-Universitaria di Cagliari, Monserrato, Cagliari, Italy.

Abstract

BACKGROUND:

We assessed the impact on survival of angiogenesis and inflammation-related factors, particularly LDH serum levels, platelet, neutrophil and lymphocyte counts, and neutrophil-to-lymphocyte ratio (NLR), in metastatic colorectal cancer patients receiving regorafenib monotherapy.

METHODS:

LDH serum levels, neutrophil, lymphocyte and platelet counts were collected at the start of regorafenib monotherapy. Cut-off values were calculated by ROC curve analysis. Survival analyses were performed by Kaplan-Meier method, and multivariate analysis by Cox method.

RESULTS:

A total of 208 patients were eligible for analysis. Among factors who were related with worse overall survival and who maintained their role at the multivariate analysis, high platelet count (Exp(b):1.4963, 95% CI:1.0130-2.2103, p = 0.0439) and high neutrophil/lymphocyte ratio (Exp(b):1.6963, 95% CI:1.0757-2.6751, p = 0.0237) were those who more deeply were related to worse overall survival. High lymphocyte count (Exp(b):0.4527, 95% CI:0.2801-0.7316, p = 0.0013) was correlated with improved overall survival.

CONCLUSIONS:

High neutrophil, high platelet, low lymphocyte count and/or high NLR may represent negative prognostic factors in patients receiving regorafenib monotherapy. It is advisable that these factors are taken into account in the design of subsequent trials in colorectal cancer patients receiving this drug.

KEYWORDS:

LDH; colorectal cancer; neutrophil/lymphocyte ratio; prognostic factors; regorafenib

PMID:
26334693
PMCID:
PMC4741819
DOI:
10.18632/oncotarget.5053
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center